NEW YORK (GenomeWeb) – A draft document published today by the UK's National Institute for Health and Care Excellence (NICE) reverses a previous endorsement for the use of Genomic Health's Oncotype Dx test in guiding chemotherapy decisions for breast cancer patients.
To read the full story....
...and receive Daily News bulletins.
Already have a 360Dx or GenomeWeb account?
Login Now.
Don't have a 360Dx or GenomeWeb account?
Register for Free.